share_log

HC Wainwright & Co. Reiterates Buy on Revance Therapeutics, Maintains $12 Price Target

Moomoo 24/7 ·  Feb 29 15:18

HC Wainwright & Co. analyst Douglas Tsao reiterates Revance Therapeutics (NASDAQ:RVNC) with a Buy and maintains $12 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment